CD274 and lung carcinoma: The current guidelines for lung carcinoma propose the analysis of PD-L1 expression in every case of NSCLC, using a validated PD-L1 immunohistochemistry expression assay to optimize selection for treatment with immune checkpoint inhibitors [28].